The Phase III trial of clostridial collagenase for residual stage Dupuytren's disease aims to establish its safety and efficacy compared to placebo. With an estimated enrollment of 72 patients, the study's outcomes could significantly impact the treatment landscape for Dupuytren's disease, a condition affecting a notable segment of the population, particularly older adults. If successful, this therapy may capture a substantial share of the market currently dominated by surgical interventions. The results could also enhance the sponsor's reputation and lead to potential partnerships or licensing opportunities. Given the rarity of Dupuytren's disease, the asset may qualify for orphan drug designation, providing additional market exclusivity and incentives.